Chr. Hansen Holding A/S (CRTSF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Chr. Hansen Holding A/S (CRTSF) with AI Score 48/100 (Weak). Chr. Hansen Holding A/S develops and sells natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries. Market cap: 0, Sector: Basic materials.
Last analyzed: Mar 17, 2026Chr. Hansen Holding A/S (CRTSF) Materials & Commodity Exposure
Chr. Hansen Holding A/S is a global bioscience company specializing in natural ingredient solutions for the food, health, and agricultural sectors. With a focus on cultures, enzymes, and probiotics, the company enhances the taste, nutrition, and shelf life of various products, maintaining a strong market presence in diverse industries.
Investment Thesis
Chr. Hansen Holding A/S presents a compelling investment case based on its strong market position in the bioscience industry and its focus on natural ingredient solutions. The company's consistent profitability, demonstrated by a 17.0% profit margin and a 54.2% gross margin, highlights its operational efficiency. A key value driver is the increasing demand for natural and sustainable ingredients in the food, health, and agricultural sectors. Growth catalysts include the company's strategic collaboration with UPL Ltd. to develop bio solutions for sustainable agriculture. Potential risks include fluctuations in raw material prices and increasing competition within the specialty chemicals sector. Chr. Hansen's low beta of 0.33 suggests relatively low volatility compared to the overall market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $10.44 billion, reflecting its significant presence in the bioscience industry.
- P/E ratio of 42.76, indicating investor expectations for future earnings growth.
- Profit margin of 17.0%, showcasing the company's ability to generate profits from its revenue.
- Gross margin of 54.2%, reflecting efficient cost management in the production of its natural ingredient solutions.
- Beta of 0.33, suggesting lower volatility compared to the broader market.
Competitors & Peers
Strengths
- Strong market position in bioscience industry.
- Diverse product portfolio of natural ingredient solutions.
- Global presence and distribution network.
- Commitment to innovation and sustainability.
Weaknesses
- Reliance on specific industries (food, health, agriculture).
- Exposure to fluctuations in raw material prices.
- Limited dividend yield compared to some competitors.
- OTC market trading may present liquidity challenges.
Catalysts
- Ongoing: Increasing demand for natural and sustainable ingredients in the food and health industries.
- Ongoing: Strategic collaboration with UPL Ltd. to develop bio solutions for sustainable agriculture.
- Upcoming: Potential expansion into new geographic markets in Asia Pacific and Latin America.
- Ongoing: Growth in the probiotics market driven by increasing consumer awareness of health benefits.
- Upcoming: Development of new and innovative solutions for the food cultures and enzymes market.
Risks
- Potential: Fluctuations in raw material prices impacting profitability.
- Potential: Increasing competition from other bioscience companies.
- Potential: Regulatory changes affecting the food and health industries.
- Potential: Economic downturns impacting consumer spending.
- Ongoing: OTC market trading may present liquidity challenges.
Growth Opportunities
- Expansion in Sustainable Agriculture: Chr. Hansen's collaboration with UPL Ltd. to develop microbial-based bio solutions for sustainable agriculture presents a significant growth opportunity. The global market for bio pesticides is projected to reach $10 billion by 2027, driven by increasing demand for eco-friendly farming practices. This partnership allows Chr. Hansen to leverage its bioscience expertise to capture a share of this rapidly expanding market, offering farmers sustainable alternatives to traditional chemical pesticides.
- Increasing Demand for Probiotics: The global probiotics market is expected to reach $91.09 billion by 2032, growing at a CAGR of 7.4% from 2023. Chr. Hansen is well-positioned to capitalize on this trend through its Health & Nutrition segment, which produces probiotic products for dietary supplements, infant formula, and animal feed. As consumer awareness of the health benefits of probiotics increases, Chr. Hansen can expand its market share by developing innovative probiotic solutions and strengthening its distribution channels.
- Growth in the Food Cultures and Enzymes Market: The market for food cultures and enzymes is driven by the increasing demand for processed and packaged foods with enhanced taste, texture, and shelf life. Chr. Hansen's Food Cultures & Enzymes segment can leverage this trend by developing customized solutions for the dairy, beverage, and bakery industries. The company's expertise in fermentation and enzyme technology provides a competitive advantage in meeting the evolving needs of food manufacturers.
- Geographic Expansion in Emerging Markets: Chr. Hansen has the opportunity to expand its presence in emerging markets, particularly in the Asia Pacific and Latin America regions. These markets are experiencing rapid economic growth and increasing demand for natural ingredient solutions in the food, health, and agricultural sectors. By establishing local partnerships and tailoring its product offerings to meet regional preferences, Chr. Hansen can tap into new revenue streams and diversify its geographic footprint.
- Strategic Acquisitions and Partnerships: Chr. Hansen can pursue strategic acquisitions and partnerships to expand its product portfolio, enhance its technological capabilities, and strengthen its market position. By acquiring companies with complementary technologies or market access, Chr. Hansen can accelerate its growth and innovation efforts. Strategic partnerships with research institutions and industry players can also provide access to new technologies and market opportunities.
Opportunities
- Expansion in sustainable agriculture and bio solutions.
- Increasing demand for probiotics and natural ingredients.
- Geographic expansion in emerging markets.
- Strategic acquisitions and partnerships.
Threats
- Increasing competition from other bioscience companies.
- Regulatory changes affecting the food and health industries.
- Economic downturns impacting consumer spending.
- Potential disruptions in supply chains.
Competitive Advantages
- Proprietary technology in fermentation and enzyme production.
- Strong brand reputation for quality and innovation.
- Extensive portfolio of natural ingredient solutions.
- Global distribution network and customer relationships.
About CRTSF
Founded in 1843 and headquartered in Hørsholm, Denmark, Chr. Hansen Holding A/S has evolved into a leading bioscience company with a global footprint. The company develops and provides natural ingredient solutions to the food, nutritional, pharmaceutical, and agricultural industries. Chr. Hansen operates through two primary segments: Food Cultures & Enzymes, and Health & Nutrition. The Food Cultures & Enzymes segment focuses on producing and selling cultures, enzymes, and probiotic products that enhance the taste, flavor, texture, shelf life, nutritional value, and health benefits of food products, particularly in the dairy industry. The Health & Nutrition segment offers solutions for dietary supplements, over-the-counter pharmaceuticals, infant formula, animal feed, and plant protection. Chr. Hansen's commitment to innovation and sustainability is underscored by its strategic collaboration with UPL Ltd. to develop and commercialize microbial-based bio solutions for sustainable agriculture. With a long history of pioneering bioscience, Chr. Hansen continues to expand its offerings and global reach, serving a diverse range of customers across Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific region.
What They Do
- Develops natural ingredient solutions for the food industry.
- Produces cultures and enzymes for dairy products.
- Offers probiotic products for dietary supplements.
- Provides solutions for the pharmaceutical industry.
- Develops products for animal feed and plant protection.
- Collaborates on microbial-based bio solutions for agriculture.
- Enhances the taste, texture, and shelf life of food products.
Business Model
- Develops and manufactures natural ingredients.
- Sells products directly to food, health, and agricultural companies.
- Generates revenue through product sales and licensing agreements.
- Invests in research and development to innovate new solutions.
Industry Context
Chr. Hansen Holding A/S operates within the specialty chemicals industry, which is characterized by innovation, sustainability, and increasing demand for natural ingredients. The global market for specialty chemicals is driven by the food, health, and agricultural sectors, with a growing emphasis on bio-based solutions. Chr. Hansen competes with companies like ACHHY (Ajinomoto Co., Inc.), ASGLF (Associated British Foods plc), AWCMY (Archer-Daniels-Midland Company), BOLIF (Koninklijke DSM N.V.), and HMTLY (Hormel Foods Corporation), each vying for market share through unique product offerings and strategic partnerships. The industry is witnessing a shift towards sustainable practices and consumer preferences for healthier, natural products, positioning Chr. Hansen favorably due to its focus on bioscience and natural ingredient solutions.
Key Customers
- Food manufacturers in the dairy, beverage, and bakery industries.
- Dietary supplement companies producing probiotic products.
- Pharmaceutical companies developing over-the-counter medications.
- Agricultural companies seeking sustainable plant protection solutions.
Financials
Chart & Info
Chr. Hansen Holding A/S (CRTSF) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Friday
· Feb 28, 2020
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CRTSF.
Price Targets
Wall Street price target analysis for CRTSF.
MoonshotScore
What does this score mean?
The MoonshotScore rates CRTSF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Mauricio Graber
CEO
Mauricio Graber serves as the CEO of Chr. Hansen Holding A/S. His career spans various leadership roles in the food and beverage industry. Before joining Chr. Hansen, he held significant positions at Nestlé, including Regional Business Head for the Infant Nutrition division in Latin America and CEO of Nestlé Mexico. Graber brings extensive experience in strategy, operations, and market development to his role at Chr. Hansen.
Track Record: Under Mauricio Graber's leadership, Chr. Hansen has focused on strengthening its position as a leading bioscience company and expanding its presence in sustainable agriculture. He has overseen strategic collaborations, such as the partnership with UPL Ltd., to develop innovative bio solutions. Graber has also emphasized the importance of sustainability and innovation in driving long-term growth for the company.
CRTSF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Chr. Hansen Holding A/S (CRTSF) may have limited reporting requirements or may not meet the listing standards of higher tiers like OTCQX or OTCQB. Unlike stocks listed on major exchanges such as the NYSE or NASDAQ, OTC Other stocks often have less stringent financial and regulatory oversight, which can result in higher risks for investors due to potential information asymmetry and reduced transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for lower liquidity and higher price volatility.
- Increased risk of fraud or manipulation.
- Lack of regulatory oversight compared to major exchanges.
- Information asymmetry and difficulty in conducting due diligence.
- Verify the company's financial statements and reporting history.
- Assess the company's management team and corporate governance practices.
- Review the company's business model and competitive landscape.
- Analyze the company's risk factors and potential liabilities.
- Evaluate the company's liquidity and trading volume on the OTC market.
- Consult with a financial advisor to assess the suitability of the investment.
- Confirm the company's legal and regulatory compliance.
- Established history as a bioscience company since 1843.
- Global presence and operations in multiple regions.
- Strategic collaborations with reputable companies like UPL Ltd.
- Focus on innovation and sustainability.
- Experienced management team led by CEO Mauricio Graber.
CRTSF Basic Materials Stock FAQ
What does Chr. Hansen Holding A/S do?
Chr. Hansen Holding A/S is a bioscience company that develops and sells natural ingredient solutions for the food, nutritional, pharmaceutical, and agricultural industries. The company operates through two segments: Food Cultures & Enzymes, which produces cultures, enzymes, and probiotics for the food industry, and Health & Nutrition, which offers solutions for dietary supplements, pharmaceuticals, infant formula, animal feed, and plant protection. Chr. Hansen's products enhance the taste, texture, shelf life, and nutritional value of various consumer goods.
What do analysts say about CRTSF stock?
Analyst coverage of CRTSF may be limited due to its OTC listing. However, key valuation metrics such as the P/E ratio of 42.76 indicate investor expectations for future earnings growth. Growth considerations include the company's expansion in sustainable agriculture and the increasing demand for probiotics and natural ingredients. Investors should conduct their own due diligence and consider the risks associated with OTC trading before making investment decisions. Analyst consensus is not available.
What are the main risks for CRTSF?
The main risks for Chr. Hansen Holding A/S include fluctuations in raw material prices, increasing competition from other bioscience companies, and regulatory changes affecting the food and health industries. Economic downturns could also impact consumer spending and demand for the company's products. Additionally, trading on the OTC market presents liquidity challenges and potential information asymmetry. Investors should carefully assess these risks before investing in CRTSF.
What are the key factors to evaluate for CRTSF?
Chr. Hansen Holding A/S (CRTSF) currently holds an AI score of 48/100, indicating low score. Key strength: Strong market position in bioscience industry.. Primary risk to monitor: Potential: Fluctuations in raw material prices impacting profitability.. This is not financial advice.
How frequently does CRTSF data refresh on this page?
CRTSF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CRTSF's recent stock price performance?
Recent price movement in Chr. Hansen Holding A/S (CRTSF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Strong market position in bioscience industry.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CRTSF overvalued or undervalued right now?
Determining whether Chr. Hansen Holding A/S (CRTSF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CRTSF?
Before investing in Chr. Hansen Holding A/S (CRTSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited or less reliable than exchange-listed data.